C Ottensmeier
Overview
Explore the profile of C Ottensmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matthews L, Noble F, Tod J, Jaynes E, Harris S, Primrose J, et al.
Br J Cancer
. 2015 Dec;
113(12):1746.
PMID: 26695557
No abstract available.
2.
Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, et al.
Eur J Cancer
. 2015 Aug;
51(16):2404-12.
PMID: 26278648
The United Kingdom (UK) uveal melanoma guideline development group used an evidence based systematic approach (Scottish Intercollegiate Guidelines Network (SIGN)) to make recommendations in key areas of uncertainty in the...
3.
McCormick Matthews L, Noble F, Tod J, Jaynes E, Harris S, Primrose J, et al.
Br J Cancer
. 2015 Jun;
113(1):107-18.
PMID: 26110972
Background: Oesophageal adenocarcinoma (OAC) is one of the fastest rising malignancies with continued poor prognosis. Many studies have proposed novel biomarkers but, to date, no immunohistochemical markers of survival after...
4.
Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, et al.
Eur J Cancer
. 2014 Apr;
50(10):1717-1721.
PMID: 24726055
Introduction: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a...
5.
Bullock M, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, et al.
Br J Cancer
. 2013 Jul;
109(2):387-94.
PMID: 23828518
Background: In previous studies, the Forkhead/winged-helix-box-class-O3 (FOXO3) transcription factor has displayed both tumour suppressive and metastasis-promoting properties.To clarify its role in human colorectal cancer (CRC) progression, we examined in vivo...
6.
Britten C, Janetzki S, Butterfield L, Ferrari G, Gouttefangeas C, Huber C, et al.
Immunity
. 2012 Jul;
37(1):1-2.
PMID: 22840835
No abstract available.
7.
ODay S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al.
Br J Cancer
. 2011 Jul;
105(3):346-52.
PMID: 21750555
Background: α(v) integrins are involved in angiogenesis and melanoma tumourigenesis. Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody. Methods: In a multicentre, randomised, phase II study, stage IV...
8.
Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, et al.
Br J Cancer
. 2011 Jul;
105(3):353-9.
PMID: 21750549
Method: The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study...
9.
Mitra A, Conway C, Walker C, Cook M, Powell B, Lobo S, et al.
Br J Cancer
. 2010 Sep;
103(8):1229-36.
PMID: 20859289
Background: To optimise predictive models for sentinal node biopsy (SNB) positivity, relapse and survival, using clinico-pathological characteristics and osteopontin gene expression in primary melanomas. Methods: A comparison of the clinico-pathological...
10.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, et al.
Cancer Immunol Immunother
. 2010 Jun;
59(10):1489-501.
PMID: 20549207
No consensus has been reached on how to determine if an immune response has been detected based on raw data from an ELISPOT assay. The goal of this paper is...